Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 11/20 | 0.48 |
| ▸ | CA1 | P00915 | 11/20 | 0.48 |
| ▸ | CA2 | P00918 | 11/20 | 0.48 |
| ▸ | CA9 | Q16790 | 10/20 | 0.48 |
| ▸ | CA6 | P23280 | 6/20 | 0.48 |
| ▸ | CA7 | P43166 | 6/20 | 0.48 |
| ▸ | CA5A | P35218 | 5/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.48 |
| ▸ | CA3 | P07451 | 4/20 | 0.48 |
| ▸ | CA4 | P22748 | 4/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.48 |
| ▸ | PTGES2 | Q9H7Z7 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.43 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3534066 | 0.98 | CA12 (0.47) | CA12CA1CA2CA9CA6 | |
| SCHEMBL6063748 | 0.98 | CA12 (0.47) | CA12CA1CA2CA9CA6 | |
| SCHEMBL13969592 | 0.83 | KDM4E (0.52) | CA12CA1CA2CA9CA6 | |
| SCHEMBL1200665 | 0.81 | TRPV4 (0.53) | CA12CA1CA2CA9PTGES2 | |
| SCHEMBL12186139 | 0.81 | L3MBTL1 (0.44) | CA1CA2CA9ALDH1A1MEN1 | |
| SCHEMBL29907222 | 0.81 | TRPV4 (0.53) | CA12CA1CA2CA9PTGES2 | |
| SCHEMBL9326968 | 0.80 | KDM4E (0.58) | CA12CA1CA2CA9CA6 | |
| SCHEMBL841673 | 0.79 | CA2 (0.51) | CA12CA1CA2CA9CA6 | |
| SCHEMBL30678376 | 0.79 | HSD11B1 (0.39) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL30442459 | 0.79 | SMN1; SMN2 (0.39) | CA12CA1CA2CA9PTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008065631-A1 | METHOD AND COMPOSITION FOR TREATING WATER | KATZ JOANNE RAPHAEL (ZA) | 2008-06-05 | — | — | WO | claimed |
| WO-1996014742-A1 | SOLID HALOGEN-CONTAINING DISINFECTANT/POLYVINYLCHLORIDE RESIN COMPOSITIONS | OLIN CORPORATION (US) | 1996-05-23 | — | — | WO | claimed |
| WO-2024145461-A2 | COMPOSITIONS FOR TREATING OSTEOPOROSIS AND BONE LOSS AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-4377356-A1 | OSMR-SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240165256-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | IMMUNOGEN INC (US) | 2024-05-23 | — | — | US | disclosed |
| EP-4363454-A1 | POLYPEPTIDES TARGETING CD70-POSITIVE CANCERS | Board of Regents, The University of Texas System (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4352086-A1 | METHODS AND COMPOSITIONS FOR TREATING FIBROSIS | The University of Chicago (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4347643-A1 | HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO STREPTOLYSIN O AND METHODS OF USE | The United States Government as represented by the Department of Veterans Affairs (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4326306-A1 | METHODS AND COMPOSITIONS COMPRISING MHC CLASS I PEPTIDES | Board of Regents, The University of Texas System (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4320145-A1 | METHODS AND COMPOSITIONS COMPRISING MHC CLASS I PEPTIDES | Board of Regents, The University of Texas System (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023010093-A9 | OSMR-SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-1332368-A2 | METHODS FOR DETECTING THE EFFICACY OF ANTICANCER TREATMENTS | Board of Regents, The University of Texas System (US) | 2003-08-06 | — | — | EP | disclosed |
| WO-2003024993-A2 | MEASURING CIRCULATING THERAPEUTIC ANTIBODY, ANTIGEN AND ANTIGEN/ANTIBODY COMPLEXES USING ELISA ASSAYS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002074789-A2 | USE OF MONOCLONAL ANTIBODIES AND FUNCTIONAL ASSAYS FOR PREDICTION OF RISK OF OPPORTUNISTIC INFECTION | BAYLOR COLLEGE OF MEDICINE (US) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002039121-A2 | METHODS FOR DETECTING THE EFFICACY OF ANTICANCER TREATMENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-2002036172-A2 | ROTAVIRUS ENTEROTOXIN NSP4 AND METHODS OF USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2002-05-10 | — | — | WO | disclosed |
| EP-0682257-B1 | Methods of detecting collagen degradation in vivo | WASHINGTON RES FOUND (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0890840-A2 | Assaying for collagen degradation in vivo | Washington Research Foundation (US) | 1999-01-13 | — | — | EP | disclosed |
| EP-0682257-A1 | Methods of detecting collagen degradation in vivo | Washington Research Foundation (US) | 1995-11-15 | — | — | EP | disclosed |
| EP-0682256-A1 | Methods of detecting collagen degradation in vivo | Washington Research Foundation (US) | 1995-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165256-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | ADAM9, TMPRSS15, ADAM17 | CA12 100/4885CA1 366/4885CA2 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.